Abstract: Clinicians in pulmonary medicine frequently confront the challenge of screening, diagnosis, and management of pulmonary hypertension (PH) in sarcoidosis patients who present with unexplained dyspnea. Sarcoidosis-associated pulmonary hypertension (SAPH) is most prevalent in patients with pulmonary fibrosis, although it can be independent of airflow obstruction or restriction. SAPH is independently associated with significantly increased mortality and decreased functional capacity, outcomes that can be mitigated by early detection and focused treatment. In this review, we discuss the pathophysiology of SAPH, which may resemble pulmonary arterial hypertension and secondary causes of PH. We offer a screening algorithm for SAPH and advocate for detailed assessment of the cause of PH in each patient before choice of an individualized treatment plan. We note that treatment of sarcoidosis by immune suppression is typically insufficient to treat SAPH adequately. We discuss the secondary causes of SAPH such as left heart disease, sleep-disordered breathing, and thromboembolic disease, and the evidence for use of PH-specific therapy in select cases of SAPH. Management of SAPH by clinicians experienced in PH, with early referral to transplantation in refractory cases, is advised.
S
arcoidosis is an immune-mediated disease believed to be precipitated by unknown environmental triggers in patients with a susceptible genetic background. 1, 2 The multisystemic manifestations of sarcoidosis are unified by the presence of sterile, typically noncaseating granulomas on biopsy of involved tissue. 3 Granulomatous inflammation and fibrosis in the pulmonary vasculature, airways, interstitium, and other anatomic locations result in pulmonary hypertension (PH) for a significant number of sarcoidosis patients.
The epidemiology of sarcoidosis and PH shows that sarcoidosis-associated pulmonary hypertension (SAPH) is prevalent, highly morbid, and deadly in patients who are commonly seen by pulmonologists. Between 5.7% and 28.3% of all sarcoidosis patients develop SAPH, with a wide range of prevalence reported across several single-center studies. [4] [5] [6] Sarcoidosis patients with pulmonary fibrosis have the highest prevalence of SAPH, 7 although SAPH can also occur in the absence of significant lung disease. In sarcoidosis patients referred for lung transplant, SAPH was present in 73.8%. 8 Patients with SAPH have higher oxygen requirements and more functional disabilities in comparison with sarcoidosis patients with end-stage lung disease, but without PH. 8 SAPH ultimately results in excess mortality. 9 Patients with SAPH incur a marked 7-fold increase in risk for all-cause mortality compared with sarcoidosis patients without PH, even when adjusted for age and pulmonary function. 10 Patients with SAPH suffer high morbidity and mortality for several reasons. First, SAPH is a complex disease. As discussed below, sarcoidosis falls within the 2013 World Health Organization (WHO) group V category of pulmonary hypertensive disorders due to multiple etiologies. 11 Thus, each sarcoidosis patient requires an individualized assessment of mechanisms driving their PH. For example, SAPH can result from pulmonary vascular infiltration or obliteration, altered flow dynamics because of bulky lymphadenopathy or lung fibrosis, and cardiac or extracardiac sarcoidosis. Astute clinicians recognize which factors contribute the most to SAPH for the individual, and direct the treatment plan accordingly. Second, treatment of SAPH is informed by a select few highquality studies, with most evidence for PH-specific therapy extrapolated from studies in group 1 pulmonary arterial hypertension (PAH) patients. Robust phenotypic clustering of SAPH patients, followed by randomized-controlled trials of PH-specific therapies in SAPH remains a great unmet clinical need.
In this review, we summarize an evidence-based approach to the diagnosis and management of SAPH. We describe the disease pathogenesis of SAPH in detail because understanding these mechanisms practically informs SAPH phenotype categorization and treatment decisions. Where appropriate, we highlight areas of controversy and future research in the field.
PATHOGENESIS OF PULMONARY HYPERTENSION IN SARCOIDOSIS
The WHO defines PH by a mean pulmonary artery pressure (MPAP) of ≥ 25 mm Hg at rest. 11, 12 Exercise-based definitions are excluded because of lack of standardized exercise measurements and consensus on cut-off values for exerciseinduced PH. 11 PH is then further divided into 5 distinct WHO groups, classified by etiology (Table 1) . SAPH is classified as group V PH because of its multifactorial mechanisms. Thus, SAPH may present with elements of each of the other 4 categories of PH depending on the particular clinical manifestations present in the patient. In the following sections, we review these pathophysiologic categories.
and medial thickening, smooth muscle hyperplasia, pathologic muscularization of nonmuscularized arterioles, and intimal fibrosis and proliferation. 13 PAH is also characterized by marked endothelial dysfunction, including impaired nitric oxide generation and in situ thrombosis. In late-stage disease, disorganized whorls of endothelial cells called plexiform lesions develop. Pathologic angiogenesis is also a hallmark of PAH. 14 Whether endothelial dysfunction is a primary causative feature of PH or a secondary response to elevated PA pressures remains controversial. However, it is believed that aberrant vascular remodeling over time elevates PA pressures.
On pathologic review, SAPH frequently shows granulomas in the walls of the pulmonary vasculature. Granulomatous vessel involvement may affect the entirety of the pulmonary vascular tree, from elastic arteries to the collecting venules. 15, 16 Granulomas are most commonly found in the lymphatic and venous systems, where they can mimic pulmonary veno-occlusive disease. 16 Granulomatous inflammation has been described in all layers of the vasculature and can circumferentially encase the vessel lumen and cause vessel fibrosis, leading to increased PVR. Some pathologic hallmarks of PAH are noted in SAPH, including the findings of plexiform lesions and intimal fibrosis. 16, 17 Right heart catheterization (RHC) is required to establish the diagnosis of PH. Current guidelines recommend vasoreactivity testing for patients with idiopathic, heritable, or drug toxic PH, in an experienced center setting, and in patients who are not in right heart failure. Vasoreactivity is defined by a decrease in the MPAP to ≤ 40 mm Hg accompanied by an absolute decrease of 10 mm Hg in response to inhaled nitric oxide or IV epoprostenol during RHC. 18 Although vasoreactivity has been described in SAPH, there is currently no significant amount of data on the benefit of calcium channel blockers in vasoreactive SAPH patients. 19, 20 The vasodilatory response to inhaled nitric oxide in some patients nonetheless suggests the possibility of successfully treating select SAPH patients with pulmonary vasodilators (PVs). As in patients with PAH, patients with SAPH should never be treated empirically with calcium channel blockers or PVs as these may precipitate worsening heart failure or pulmonary edema when utilized in the incorrect setting.
Pulmonary Hypertension Secondary to Left Heart Disease
The prevalence of cardiac sarcoidosis may be underrecognized and it is estimated that 20% to 25% of sarcoidosis patients have silent cardiac involvement compared with ∼5% with manifest disease. 21 The 3 most common clinical manifestations of cardiac sarcoid are conduction disease, ventricular arrhythmias, and heart failure. 21 Sarcoidosis may result in heart failure symptoms with either reduced or preserved left ventricular ejection fraction. The co-occurrence of PH in sarcoidosis patients with left heart failure is unclear, with estimates ranging from 23% to 79%. 22 This is true for a variety of reasons, including different diagnostic criteria between studies and the heterogeneity of the populations studied.
The diagnosis of left heart disease-associated PH depends on having a PA wedge pressure > 15 mm Hg. 11 This retrograde transmission of pressure from the left heart is mostly driven by diastolic dysfunction, and thus the maintenance of euvolemia is a key component of management. 23 In addition, increased retrograde pressure can trigger the release of vasoconstrictive molecules that lead to a "precapillary" component of PH in leftsided heart failure. 24 Furthermore, if PH from poorly controlled heart failure persists over time, there is adaptive vascular remodeling that is likely permanent. 13 The treatment for WHO Group II PH involves treatment of heart failure, and thus medications such as diuretics, afterload reduction agents, and beta blockers are the mainstays of treatment.
It is important to note that primary impact on the right ventricle from cardiac sarcoidosis is also described in patients without left ventricle involvement or pulmonary function impairment to otherwise explain significant right ventricular strain. 25, 26 The management of primary right ventricular dysfunction is beyond the scope of this review.
Pulmonary Hypertension Because of Chronic Lung Disease or Hypoxemia
Patients who develop parenchymal lung disease from sarcoidosis are at greatest risk of developing PH, and indeed, the majority of patients with SAPH have evidence of pulmonary disease. 7, 8 The primary mechanism for this is believed to be destruction of vasculature from the lung disease, resulting in hypoxemia from ventilation/perfusion mismatch. Thus, Pulmonary hypertension is defined by the World Health Organization as a mean pulmonary artery pressure ≥ 25 as measured by right heart catheterization. The diagnosis of pulmonary arterial hypertension (group 1) also requires measured pulmonary vascular resistance of > 3 Wood units. Items in bold represent etiologies that have been implicated in sarcoidosis-associated pulmonary hypertension.
PAH indicates pulmonary arterial hypertension.
supplemental oxygen should be used for patients when necessary. Architectural distortion of the pulmonary vasculature can also increase PVR. Dyspnea out of proportion to lung disease and accompanied by exertional hypoxemia should raise suspicion for the development of SAPH, particularly in sarcoidosis patients whose dyspnea seems refractory to immune suppression. A formal PH workup should be pursued when there is suspicion for SAPH in patients with parenchymal lung disease as using imaging to diagnose PH in fibrotic lung disease is not sufficiently reliable. This has been found in idiopathic pulmonary fibrosis, where radiographic markers did not predict PH. 27 In addition, there may be concomitant, but separate involvement of the pulmonary vasculature and lung parenchyma in SAPH. Although parenchymal lung disease is associated strongly with SAPH, a full evaluation of the potential causes of PH should be pursued, given the multiple etiologies by which sarcoidosis may cause SAPH. Sarcoidosis patients are also noted to have increased rates of sleep-disordered breathing. [28] [29] [30] As a result, their risk of developing PH secondary to nocturnal hypoxemia from obstructive sleep apnea is increased and is further compounded by the potential worsening of obstructive sleep apnea from corticosteroids used to treat the disease. 30 Patients who have congestive heart failure also have a higher risk of sleep-disordered breathing, thus providing another mechanism by which sarcoidosis may contribute toward the development of PH. 31 
Pulmonary Hypertension Because of Chronic Thromboembolic Pulmonary Hypertension Disease
Sarcoidosis confers an increased risk of venous thromboembolism, believed to be commensurate with active inflammation promoting a hypercoagulable state. 32 Swigris et al 33 found pulmonary embolism in 2.5% of United States decedents with sarcoidosis. A recent analysis of the Olmstead county cohort in Minnesota reported a 3-fold increase in the hazard ratio of venous thromboembolism for patients with sarcoidosis, 34 whereas in the United Kingdom, sarcoidosis patients younger than 65 years of age had a risk ratio of 2.0 for pulmonary embolism (95% confidence interval, 1.1-3.4). 35 Therefore, sarcoidosis patients are at increased risk of developing chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH presents on a spectrum ranging from central obstruction of the pulmonary vasculature to small emboli distributed among the microvasculature. Central emboli may be amenable to pulmonary endarterectomy, whereas disease of the microvasculature requires lifelong anticoagulation and is best detected through a ventilation-perfusion scan. An additional medical treatment for CTEPH is the soluble guanylyl cyclase activator riociguat, which, in studies of nonsarcoidosis PH, was associated with improved WHO functional class, increased 6-minute walk distance, and improved hemodynamics. 36 Riociguat is currently considered appropriate for use in patients with CTEPH who are nonoperable candidates or who have failed pulmonary endarterectomy. Concordant with guidelines for PH evaluation, ventilation-perfusion scanning to detect CTEPH is warranted in all patients with PH. If indeterminate or multiple perfusion defects are present, computed tomographic (CT) angiography, followed by referral to a CTEPH center is advised. 37, 38 Other Mechanisms of Sarcoidosis-associated Pulmonary Hypertension Sarcoidosis may present with marked thoracic lymphadenopathy and fibrosing mediastinitis. In these cases, architectural distortion on major branches of the pulmonary circulation imposes physical impedance to pulmonary blood flow, leading to pulmonary stenosis and segmental PH. 39, 40 The presence of significant thoracic lymphadenopathy or a chest bruit are clues to anatomic pulmonary arterial obstruction. PA stenting has been shown to be effective by several groups, achieving a sustained decrease in the PA pressure. 41, 42 Although liver involvement has been well described, cirrhosis is a rare complication of sarcoidosis, comprising <1% of cases. 43 No cases of portopulmonary hypertension definitively attributed to sarcoidosis have been reported, although a different cause of hypoxemia, the hepatopulmonary syndrome, has been described. 43, 44 Although the possibility of portopulmonary hypertension should be considered in sarcoidosis patients with cirrhosis, the overall incidence of this etiology seems to be quite rare.
Finally, chronic anemia can lead to high output heart failure. Patients with sarcoidosis may have a mild degree of anemia from their disease that can be exacerbated by agents commonly used to treat sarcoidosis such as methotrexate or azathioprine.
SCREENING FOR SARCOIDOSIS-ASSOCIATED PULMONARY HYPERTENSION
The gold standard for the diagnosis of PH is RHC. This section focuses on key aspects of the patient's clinical presentation and screening tests when considering referral for RHC. Figure 1 summarizes a SAPH screening algorithm for sarcoidosis patients presenting with dyspnea.
Symptomatology and Examination
The symptoms of sarcoidosis and PH may be difficult to distinguish, but the clinician should have a low threshold of suspicion for SAPH and be vigilant for worsening dyspnea or signs of right-sided heart failure. Exertional dyspnea is a common complaint in pulmonary sarcoidosis, cardiac sarcoidosis, and in PH, thus confounding the diagnosis of SAPH. 1, 12 Similarly, chest pain and palpitations are also reported in both diseases independently. Exertional syncope is one criterion for WHO functional class IV PH, but may also occur because of cardiac conduction disease in sarcoidosis.
Signs of PH on physical examination include a loud P2, evidence of right-sided volume overload such as elevated jugular venous pressure or peripheral edema, and a right ventricular heave, but these are often findings that are discovered late in the disease course. A systematic review showed that the presence of a loud P2 or a right-sided fourth heart sound were the best physical examination correlates of PH, but most reliable in the hands of a specialist. 45 
Pulmonary Function Testing
Patients with sarcoidosis undergo routine pulmonary function tests (PFTs), which may provide clues to the presence of PH. Diffusing capacity of the lung for carbon monoxide (DLCO), forced vital capacity, and the 6-minute walk test (6MWT) have all been noted to be decreased in patients with SAPH. 4 In addition, ambulating hypoxemia is a key feature of PH. In a study of 162 patients with sarcoidosis, Bourbonnais and Samavati reported that oxygen desaturation below 90% on 6MWT correlated with an odds ratio of 12.1 (confidence interval, 3.7-19.7) of having SAPH, with a DLCO < 60% predicted showing an odds ratio of 7.3 of having PH. 4 Mirsaeidi et al 46 also identified 6MWT desaturation and low DLCO as the strongest correlates with PA systolic pressure as measured by echocardiography. Among the different parameters for PFT, it is logical that DLCO and 6MWT
Imaging
The presence of advanced lung disease on chest x-ray has been associated with SAPH by several groups. 5, 7 However, SAPH can also exist in isolation of significant lung disease. 47 The presence of significant parenchymal lung disease in patients with sarcoidosis should lead to the obtaining of a CT scan of the chest. Often, this imaging has occurred earlier in a patient's disease course before the diagnosis of sarcoidosis is made.
Numerous studies have investigated the utility of CT scan for the detection of PH, with reported associations between PA diameter and the ratio of PA to aorta. 27, 48, 49 In a study specific to sarcoidosis in which over half the patients had Scadding stage IV disease, Huitema et al 50 found that CT-measured PA diameter corrected for body surface area was the best predictor of SAPH. This recent study counters earlier literature questioning the reliability of CT scanning for the detection of PH in patients with pulmonary fibrosis. Although RHC remains the gold standard for PH diagnosis and radiographic results can only be suggestive, enlarged PA diameter on CT scan should heighten the clinicians' pretest probability of PH being present and prompt further workup.
Echocardiography
Echocardiography remains the most common means to screen for PH of all causes. 51 It is particularly useful in sarcoidosis because of the simultaneous need for assessment of cardiac sarcoidosis. Bertoli et al 52 were the first to report on the use of echocardiography in SAPH.
Echocardiography remains a screening test that should not be used for PH diagnosis because of several limitations. One notable pitfall is the use of echocardiography in the presence of fibrotic lung disease, which compromises the accuracy of echocardiography to estimate MPAP. In a cross-sectional study of idiopathic pulmonary fibrosis patients with RHC data and echocardiograms, Nathan et al 53 found that only 40% of patients had echocardiograms that reasonably estimated MPAP. In addition to this pitfall, not all patients have a regurgitant tricuspid jet, which is required for estimation of PA pressure, or adequate windows for echocardiographic estimation of right heart parameters. Despite these limitations, high estimated pulmonary pressures are likely still useful. Baughman et al 54 reported that an estimated PA systolic pressure > 50 by echocardiogram was associated with worse mortality, whereas when under 30, mortality was unchanged. Early detection of PH and cardiac sarcoidosis by noninvasive cardiac imaging is an area of 
TREATMENT OF SARCOIDOSIS-ASSOCIATED PULMONARY HYPERTENSION
The pathophysiology of SAPH holds relevance for treatment. With the exception of CTEPH, the only approved medical therapies PH are for group I or precapillary PAH. In PH secondary to left heart disease or chronic lung disease, current recommendations are to treat the underlying cause of disease. However, treatment of pulmonary sarcoidosis alone may be insufficient. For example, steroid use does not affect the burden of disease in the pulmonary vasculature of sarcoidosis patients on autopsy. 16 Furthermore, in the largest cohort study of SAPH patients, only 4/11 patients treated with immunosuppression alone showed improvements in hemodynamics. 57 As granulomatous involvement of the pulmonary vasculature and evidence of vasoreactivity suggest that SAPH may in some cases behave similar to PAH, multiple groups have investigated PAH-directed therapies in the treatment of SAPH.
The selection of patients is paramount when planning the start of PAH therapies for SAPH. Because of the multiple pathophysiological mechanisms that mediate SAPH, many patients may not respond to PH-specific therapy. Some SAPH patients, notably those with pulmonary veno-occlusive pathophysiology, acutely worsen with PV therapy. 58 Nevertheless, PVs have shown efficacy in several small studies carried out at expert centers, where patients with a precapillary SAPH phenotype most similar to PAH were carefully selected. Additional treatments for secondary PH, including diuretics for volume optimization, surgery or anticoagulation for thromboembolic disease, treatment of sleep-disordered breathing, and stenting for mechanical vascular obstruction, should be pursued when these concurrent illnesses are present.
The results of the studies investigating the treatment of SAPH with PVs show improvements in hemodynamics and functional status. The PV treatment in SAPH was not associated with harm in patients carefully selected by expert centers, although none were able to clearly achieve a mortality benefit. Many studies are limited by small populations of patients and a high dropout rate. Table 2 summarizes the major findings.
Endothelin Receptor Antagonists
Bosentan, ambrisentan, and macitentan are endothelin receptor antagonists, which block the activity of endothelin on pulmonary vascular smooth muscle. Endothelin is a potent endogenous vasoactive molecule implicated in the pathophysiology of PAH through its ability to increase pulmonary vascular tone and impact long-term effects of pulmonary vascular remodeling. 66 Bosentan and ambrisentan are among the first-line therapies in the treatment of PAH, whereas macitentan has not been studied in SAPH.
Bosentan is approved for PAH and has also shown hemodynamic benefit in PH secondary to congenital heart disease and CTEPH. 67, 68 The sole randomized clinical trial for SAPH examined the use of bosentan. This study randomized patients with SAPH diagnosed by RHC to bosentan versus placebo and measured hemodynamic and functional outcomes after 16 weeks of therapy. 54 It showed an improvement in hemodynamics with the use of bosentan, but no significant improvement in PFTs or 6MWT. Two patients who were treated with bosentan also required oxygen. Liver toxicity, a common side effect of bosentan, was not observed. The trial had a somewhat high dropout rate, with 8 of the 43 enrolled (19%) patients not being observed for the full 16 weeks. The placebo and treatment groups were similar in WHO functional class, sarcoidosis treatment, and degree of lung parenchymal involvement of sarcoidosis.
Ambrisentan has a mechanism of action similar to bosentan, but causes less liver toxicity and has also been studied in SAPH. 61 Judson and colleagues carried out an openlabel prospective study to assess the impact of ambrisentan on SAPH patients. At a follow-up period of 24 weeks, there was an improvement in WHO functional class and in quality of life. Hemodynamics were not assessed. The study was limited in large part by the high dropout rate: only 10/21 patients remained in the study through the full follow-up period. Two patients reported liver toxicity.
Phosphodiesterase Inhibitors
Phosphodiesterase inhibitors inhibit the degradation of intracellular cyclic guanylyl monophosphate in vascular smooth muscle, which leads to increased nitric oxide generation and subsequent smooth muscle relaxation. Sildenafil and tadalafil are members of this class, along with vardenafil, which is less commonly used. The results of phosphodiesterase inhibitor studies are mixed, with 1 retrospective study reporting improvement in hemodynamics, but not 6MWT. 63 A prospective case series highlighting the use of tadalafil in 12 patients noted no change in 6MWT or quality-of-life measures, although like many other studies, the dropout rate was significant. Patients on tadalafil did not worsen clinically. 62 Riociguat, a soluble guanylyl cyclase activator, also serves to increase intracellular cyclic guanylyl monophosphate and is approved in group I and group IV PH. 36 This medication has not been assessed in SAPH.
Prostacyclins
Prostacyclins, including epoprostenol, treprostinil, and iloprost, are mainstays of treatment for PAH patients with WHO functional class III or IV symptoms. Epoprostenol was the first medication approved for the treatment of PAH and has shown mortality benefit. 69 Available formulations for prostacyclin analogs include continuous IV infusion (epoprostenol and treprostinil), subcutaneous (treprostinil), oral (treprostinil), and inhaled (iloprost). More recently, selexipag, a nonprostanoid prostacyclin receptor agonist, showed good tolerance, reduced hospitalization, and slowing of disease progression, but has not been studied in SAPH. 70 Fisher et al 60 first reported on the use of epoprostenol for SAPH in 2006 in a small study of 8 patients, half of whom had stage IV radiographic disease. Of the 7 patients who underwent a vasodilator trial, 6 achieved a > 25% reduction in PVR. This was the first report of the long-term use of epoprostenol in SAPH.
Subsequently, inhaled iloprost was studied by Baughman et al 59 in a group of 22 patients and was associated with a decrement in the PVR of > 20% and improved quality of life. This study was limited by a significant dropout rate of 31% mainly because of side effects or difficulty adhering to the regimen. Only 15 patients completed the 16-week study, of whom 6 experienced a significant decrease in PVR and 5/6 showed a reduction in MPAP. A few patients showed an improved 6MWT, although this did not correlate to hemodynamic parameters. This discrepancy points to the fact that MPAP and PVR are only partially correlated with functional status, with factors such as deconditioning and lung disease also contributing toward the dyspnea of SAPH. Despite its limitations, as one of the earliest trials of PAHdirected therapy in SAPH, this study served to illustrate the potential efficacy of prostacyclins.
Bonham et al 10 published a retrospective study on the efficacy of prostacyclins in the treatment of SAPH. In this cohort of 26 patients, prostacyclin use was associated with significant decreases in PVR, decreased MPAP, improved cardiac output, and functional class. Both intravenous epoprostenol and treprostinil were used, often on a background of other PVs. This study also noted the potential for the long-term use of prostacyclins in sarcoidosis as many of the patients remained on prostacyclin therapy for years.
CONCLUSIONS
We suggest a stepwise approach to the screening, diagnosis, and selection of treatment for sarcoidosis patients suspected of having SAPH (Table 3) . We emphasize that any patient with sarcoidosis who has dyspnea should receive chest imaging and full PFTs with 6MWT. Key clues that raise suspicion for SAPH include markedly reduced DLCO below 60% of predicted, oxygen desaturation below 90% on 6MWT, and dyspnea that seems refractory to immune suppression. Echocardiography is the key noninvasive test to screen for cardiac dysfunction and PH.
Although a positive initial evaluation should prompt referral for RHC, the question remains about what to do regarding mixed or indeterminant noninvasive testing. We recommend that unexplained dyspnea in a sarcoidosis patient, Because of the heterogeneity of SAPH, future studies must clearly phenotype patients' PH and extent of pulmonary disease if we are to understand which treatments are efficacious for which patients. Figure 2 delineates an algorithm for assessment of the pathophysiology of SAPH on the basis of RHC data. PVs are currently approved for the treatment of PAH, but the majority of patients with SAPH have lung disease, where the role of PVs remains unclear. As discussed above, the literature to date supports a favorable safety profile for the use of PVs in SAPH patients who present with precapillary predominant PAH. A clear algorithm for PV initiation is not known. Patient preferences, physician experience, and side-effect profiles currently drive PV medication selection. In addition, SAPH patients with poor functional class or rapid progression are typically started on combination therapy with more than one PH-specific drug. This practice has been informed by the literature in group 1 PH, which has shown that combination up front therapy leads to a longer time to first exacerbation. 71 Referral to an experienced PH center for RHC and treatment planning is advised.
Finally, when presented with severe or refractory disease, guidelines for lung transplantation in patients with PAH may be applied to SAPH. Early lung transplant referral is made for patients with rapidly progressive PH, functional class III or IV symptoms during escalating therapy, use of parenteral targeted PH therapy, or physiology mimicking pulmonary veno-occlusive disease. 72 Sarcoidosis patients who have severe lung disease with forced vital capacity <50% predicted have been shown to respond less favorably to PH-specific therapy and should also be referred early for lung transplant consideration. 65 
